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Available online 9 July 2014Abstract Macrophages are an immune cell type found in every organ of the body. Classically, macrophages are recognised as
housekeeping cells involved in the detection of foreign antigens and danger signatures, and the clearance of tissue debris. However,
macrophages are increasingly recognised as a highly versatile cell type with a diverse range of functions that are important for tissue
homeostasis and injury responses. Recent research findings suggest that macrophages contribute to tissue regeneration and may play
a role in the activation andmobilisation of stem cells. This reviewdescribes recent advances in our understanding of the role played by
macrophages in cardiac tissuemaintenance and repair following injury.We examine the involvement of exogenous and resident tissue
macrophages in cardiac inflammatory responses and their potential activity in regulating cardiac regeneration.
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The term phagocytosis was first proposed in 1883 by Elie
Metchikoff to describe the process whereby cells clear then access article under the CC BY-NC-ND license
DAPI PH3 GFP
Figure 2 Local proliferation of cTMs. 3D perspective view of
GFP+ cTM from an adult Cx3cr1
GFP/+ mouse heart. Nuclear staining
of mitosis marker phospho-histone H3 (PH3) is shown (red).
706 A.R. Pinto et al.body of disease-causing microbes (Nobelprize.org.). In his
seminal observations, Metchikoff witnessed amoebic cells
from translucent starfish larvae surround particles from a
tangerine tree (Nobelprize.org.; Karnovsky, 1981; Tauber,
2003). Since these early observations, the macrophage –
meaning big eater in Greek – has emerged as the principal
phagocytic cell inmammals and other organisms, and is critical
for the clearance of foreign antigens and cellular debris.
Recent work, however, has extended our understanding of the
role of macrophages and demonstrated the versatility of this
unique cell type, which performs important functions in tissue
homeostasis and injury resolution, especially in the heart.
Through their interactions with other cardiac cell types,
macrophages may also play an important role in the regener-
ation of the damaged myocardium.
While macrophage ontogeny and actions are highly hetero-
geneous (Mabbott et al., 2010), all macrophages participate in
the clearance of tissue debris and the detection of pathogens
and tissue damage. Three key characteristics enable macro-
phages to perform these tissue housekeeping functions. First,
they undertake extensive macropinocytosis to sample the
local microenvironment for molecular signatures of tissue
disturbance (Lim & Gleeson, 2011). Second, they present an
array of pattern recognition receptors (PRRs) that recognise
foreign- and cell damage-associated particles, including CD14
(the LPS receptor), a range of mannose receptors and Toll-like
receptors (TLRs). This enables detection and processing of
antigens, and also presentation of antigens to T-lymphocytes
via MHC-II molecules, to activate adaptive immune responses.
Third, macrophages secrete factors that further facilitate
their role as tissue housekeepers and orchestrators of repair.Cardiac tissue macrophages
Cardiac tissue macrophages (cTMs), which are found
in abundance in the murine heart (Fig. 1), display typical
macrophage characteristics, undertaking extensive
macropinocytosis and phagocytosis to sample the local
microenvironment and express a wide array of PRRs such
as CD14, CD64 and Lpar6 (Pinto et al., 2012) that enable
rapid responses to a range of damage-associated molec-
ular patterns. However, cTMs exhibit a distinct pheno-
type, closely resembling alternatively-activated M2
macrophages that are observed at late phases of tissue
inflammation, secreting tissue salutary and immunomod-
ulatory factors (Pinto et al., 2012). Moreover, cTMsGFP Mrc1
Figure 1 Cardiac tissue macrophages (cTMs) in the uninjured
heart. 40 μmmaximum intensity projection of cTMs labelled with
GFP (green) or Mrc1 (red) from an adult Cx3cr1
GFP/+ mouse heart.
External margin of the heart (epicardium) is visible (top right).produce factors such as C1q and galectins that aid
phagocytosis of cellular debris and simultaneously damp-
en inflammation. Therefore, a presumed function of cTMs
is the inhibition of aberrant inflammatory reactions that
may lead to cell death, and promotion of cell survival.Embryonic and adult origins of cardiac tissue
macrophages
A recent revelation in the biology of tissue macrophages
has been the discovery of their remarkable proliferative
capacity (Sieweke & Allen, 2013). Using a range of approaches
including novel transgenic mouse lines that enable inducible
macrophage-specific lineage tracing, parabiosis and bone
marrow transplant experiments, independent laboratories
have demonstrated that macrophages in a range of tissues
turn-over at steady state, and are populated by local
proliferation (Hashimoto et al., 2013; Yona et al., 2013). In
the heart, we and others have recently shown that cTMs are
also proliferative (Fig. 2), dividing throughout life (Epelman et
al., 2014; Heidt et al., 2014; Pinto et al., 2014).
Macrophages that initially colonise the heart have hetero-
geneous ontogenic origins. Embryonic cTM subsets arrivewithin
the myocardium early in development from yolk sac origins at
embryonic day 7.5 (Epelman et al., 2014). Later macrophages
are colonised by haematopoietic cells originating from the
foetal liver and then bonemarrow (Epelman et al., 2014). Once
within the myocardium, a major mechanism of cTM population
expansion and maintenance is by local proliferation (Epelman
et al., 2014; Heidt et al., 2014; Pinto et al., 2014) with
monocyte-derived cells contributing minimally towards the
cTMs pool at steady-state (Epelman et al., 2014; Heidt et al.,
2014).
Intriguingly, not all cTM subsets maintain the same
proliferative activity. Cx3cr1-expressing cells comprise the
greatest proportion of proliferating cTMs (Pinto et al., 2014),
corroborating other studies that show that not all cTM subsets
have the same proliferative activity (Epelman et al., 2014).
Currently, the basis for higher proliferative potential of
different cTM subsets remains unknown. Stimulation by IL-4
signalling pathways may underlie the variable induction of
cTM proliferation: while IL-4 has minimal effect on macro-
phage proliferation in vitro, even antagonising proliferation,
707Macrophages in cardiac homeostasis, injury responses and progenitor cell mobilisationIL-4 stimulates macrophage proliferation in vivo (Jenkins et
al., 2013; Jenkins et al., 2011). Further studies are needed to
determine whether requisite components of IL-4 signalling, or
other macrophage proliferation-inducing factors, are altered
in various cTM subsets.Macrophage participation in cardiac homeostasis
While functional data examining the role of cTMs in adult
cardiac homeostasis are limited, gene expression profiling
experiments reveal a potentially important role of cTMs for
many biological processes in the uninjured heart independent
of tissue debris clearance (Pinto et al., 2012; Pinto et al.,
2014). These include angiogenesis, fibrosis and the mainte-
nance of immune quiescence.
Supporting capillary homeostasis, cTMs express a number of
pro-angiogenic factors such as Rentla/Fizz1 and IGF-1 (Pinto et
al., 2012; Teng et al., 2003; Grant et al., 1993a; Nakao-Hayashi
et al., 1992). However, unlike exogenous M2-macrophages,
cTMs do not express VEGF and may promote angiogenesis by
non-canonical VEGF-independent pathways (Nahrendorf et al.,
2007; Rymo et al., 2011; Nucera et al., 2011). Moreover, cTMs
may promote angiogenesis by direct interaction with the
endothelium. In other tissues, neuropilin 1 (Nrp1) macrophagesC. Para
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cells to bridge andmediate capillary anastomosis (Fantin et al.,
2010). Macrophages are critical for both angiogenic growth
(Sunderkotter et al., 1994) and inhibition to prevent vascular
overgrowth by inducing endothelial cell death via Wnt-
signalling pathways (Stefater et al., 2011; Rao et al., 2007). In
the heart, cTMs are in intimate contact with the dense cardiac
vascular bed and express Nrp1 (Pinto et al., 2012). Neverthe-
less, whether cTMs or exogenous macrophages are required for
the development of the dense capillary bed in the developing or
injured heart remains to be determined.
cTMs also contribute to cardiac fibrosis, a key hallmark of
cardiac senescence, which accumulates with age (Pinto et al.,
2014; Biernacka & Frangogiannis, 2011; Eghbali et al., 1989).
cTMs secrete a number of pro-fibrotic proteins such as Retnla,
IGF-1 and CCL24 and lipid mediators (such as LTC4) (Pinto
et al., 2014) that may induce fibroblast proliferation and
collagen deposition by both TGFβ1-dependent and indepen-
dent pathways. In addition, cTM expression of these genes
undergoes an age-dependent increase, particularly at the
epicardium, suggesting that cTM-mediated ECM remodelling
may alter cardiac ageing (Pinto et al., 2014). However, unlike
M2-macrophages that also exhibit a fibrogenic phenotype
(Murray & Wynn, 2011), cTMs do not directly produce arginase
1 (Arg1), which is required for the production of polyamineCardiac cells
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708 A.R. Pinto et al.precursors for collagen deposition (Odegaard & Chawla,
2011), or the potent fibrotic factor TGFβ1 (Wynn & Barron,
2010).
One of themost important activities in which cTMs are likely
to participate is immune quiescence (Fig. 3). cTMs produce a
wide array of immune-dampening molecules, including secret-
ed proteins complement component 1q (C1q), growth and
differentiation factor 15 (GDF15), galectin-1 (LGALS1) and lipid
mediators dependent on 5-lipoxygenase (ALOX5) enzyme
expression such as lipoxin A4 (LXA4), resolvin E1 and D1 (RvE1
and RvD1, respectively) and protectin D1 (PD1) (Pinto et al.,
2012; Pinto et al., 2014).
A principle mechanism whereby cTM-secreted factors
contribute to immune quiescence is by facilitating non-
phlogistic phagocytosis (phagocytosis that does not signal
inflammation) of cellular debris and dead cells that may cause
inflammation by the release of intracellular contents. C1q
mediates this process by directly binding apoptotic debris and
antibody-bound targets for phagocytosis by macrophages
(Ezekowitz et al., 1984) and inhibitingmacrophage production
of inflammatory cytokines interleukin-1α, -6 (IL-1α and IL-6,
respectively) and tumour necrosis factor α (TNFα) (Fraser
et al., 2010). In contrast, LXA4 and RvE1 and PD1 promote
non-phlogistic phagocytosis by directly stimulating macro-
phages to undertake phagocytosis, and simultaneously
inhibiting the production of inflammatory cytokines
interleukin-6, -8 (IL-6 and IL-8, respectively), monocyte
chemoattractant protein-1 (MCP-1) or interferon-γ (IFN-γ)
(Schwab et al., 2007; Godson et al., 2000). Dampening of
inflammatory cytokines is further consolidated by cTM
production of LGALS1, which also directly inhibits macrophage
production of inflammatory cytokines TNFα, IL-1β, IL-12, and
IFNγ and reduces acute inflammatory responses (Santucci et
al., 2003). LGALS1 also promotes apoptosis of potentially
self-reactive T cells during development and activated T cells
in the periphery (Santucci et al., 2003; Perillo et al., 1995;
Rabinovich et al., 1999), minimising the potential of tissue
destructive immune responses. Indeed, mice deficient in
LGALS1 have increased leukocyte infiltration following myo-
cardial injury with impaired cardiac function and post-
infarction ventricular remodelling (Seropian et al., 2013).
To further counter inflammation, cTM-secreted factors
also induce macrophages and other cells to generate
anti-inflammatory factors. For example, C1q, LXA4 and
LGALS1 induce production of anti-inflammatory cytokines
such as interleukin-27 and -10 (IL-27 and IL-10, respectively)
(Schwab et al., 2007; Son et al., 2012; Benoit et al., 2012),
which have potent paracrine activities to further dampen
inflammation. Moreover, RvD1 induces macrophage M2
polarisation (Titos et al., 2011).
Another immunomodulatory process potentially modulated
by cTMs is inhibition of leukocyte infiltration. RvE1, LGALS1
and GDF15 inhibit leukocyte cell activation and infiltration, by
multiple mechanisms including targeting chemotactic pro-
teins such as leukocyte integrin and selectins (Ariel et al.,
2005; Kempf et al., 2011; Cooper et al., 2008; Dona et al.,
2008). Depletion of these factors results in increased
leukocyte tissue infiltration and inflammation following
inflammatory stimulus (Seropian et al., 2013; Kempf et al.,
2011). Moreover, C1q treatment of cultured humanmonocytes
limits monocyte differentiation and activation (Son et al.,
2012). In summary, the suite of factors secreted by cTMs arelikely to contribute substantially to immune homeostasis in
the heart.
Macrophages and regulation of
epicardial progenitors
The mammalian epicardial niche hosts multi-potent progenitor
cells with the capacity to form endothelial cells, fibroblasts
and smooth muscle cells (Smart et al., 2011; Chong et al.,
2011). Although the relationship between macrophages and
epicardial progenitors has not been characterised, the epicar-
dium is in close contact with cTMs that are likely to modulate
the activity of epicardial progenitors in the un-injured and
injured heart (Pinto et al., 2014). cTMs constitutively express a
number of genes involved in epicardial development and stem
cell homeostasis including thymosin β4 and CEBP/β, suggesting
that cTMs may play a role in epicardial development from an
early stage and following injury (Pinto et al., 2014; Huang et
al., 2012; Smart et al., 2007).
Following cardiac injury, both resident cTMs and exogenous
macrophages may be important for epicardial responses
through paracrine mechanisms. Supporting this hypothesis,
studies have indicated that regulation of the post-injury
epicardium inflammatory milieu may be beneficial for cardiac
repair and function. Indeed, injection of supernatants from ex
vivo cultured epicardial progenitors improve cardiac repair
after injury (Zhou et al., 2011). Moreover, adenoviral
targeting of CEBP/β, a transcription factor expressed in
macrophages, at the epicardium also improves cardiac repair
(Huang et al., 2012). Both reports propose that modulation of
epicardial paracrine environment is potentially key for the
observed enhanced myocardial repair (Huang et al., 2012;
Zhou et al., 2011), underscoring the potentially important role
of cTMs and exogenous macrophages in regulating the post-MI
inflammatory milieu and tissue repair. The finding that
macrophage signalling, particularly from M2-like macro-
phages, enhances MSC survival, engraftment and potentially
also differentiation (Ben-Mordechai et al., 2013; Freytes et
al., 2013), suggests that the role ofmacrophage signallingmay
be also important for the regulation of epicardial progenitor
cells to repair the damaged myocardium.
However, cTM contribution to inflammatory responses at
the epicardium is likely to change with age. We recently
showed that cTM phenotype changes as a function of age
within the epicardium resulting in a reduction of expression in
chemokine/injury-sensing receptors including Cx3cr1, Lpar6,
CD9, Cxcr4, Itga6 and Tgfβr1 in addition to downstream signal
transduction elements (Pinto et al., 2014). Indeed, cTMs at
the epicardium from aged mice (N30 weeks old) are almost
completely lacking Cx3cr1, which regulates macrophage
responses to tissue injury (Lee et al., 2010). Therefore
age-dependent loss of Cx3cr1 and other cTM injury sensing
receptors may alter epicardial stem cell mobilisation and
cardiac tissue repair.
Moreover, with age, cTMs increase expression of pro-fibrotic
elements that may alter the epicardial extracellular matrix
(ECM). These include leukotriene c4 synthase, and Mmp9 which
are associated with the promotion of fibrosis, collagen
deposition and fibroblast proliferation (Pinto et al., 2014).
ECM modification is important for stem cell homeostasis and
function. ECM stiffness can regulate stem cell homing and
Figure 4 Diverse role of macrophages in injury resolution. (A) Macrophage mediated removal of cellular and tissue debris by
phagocytosis. (B) Angiogenesis mediated by macrophage paracrine factors and direct interaction of macrophage with endothelial tip
cells. (C) Induction of tissue fibrosis by various paracrine factors. Macrophage-derived factors can induce fibroblast proliferation and
myofibroblast differentiation, and can directly and indirectly contribute to extracellular matrix (ECM) deposition. (D) Macrophage
subtypes (‘M1’ and ‘M2’) can promote and suppress inflammation, respectively by enhancing or inhibiting leukocyte infiltration and
secretion of inflammatory mediators by local cells. (E) Various macrophage-derived factors can promote cell survival. Abbreviations:
insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), fibroblast growth factor 2 (FGF2), tumour necrosis factor α
(TNFα), interleukin 1β (IL-1β), nitric oxide (NO), matrix metallopeptidases, resistin-like molecule alpha (Retnla), transforming growth
factor β1 (TGFβ1), fibronectin 1 (FN1), tissue inhibitor of matrix metalloproteinases (TIMPs), interleukin-10 (IL-10), interleukin-1
receptor antagonist (IL-1ra), complement component 1q (C1q), C–C motif ligand 2 (CCL2) and interleukin-6 (IL-6).
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and bioavailability of growth factors and cytokines (Schultz &
Wysocki, 2009). Thus, cTM-mediated ECM remodelling of the
epicardium is another potential mechanism whereby cTMs may
regulate epicardial progenitors.Macrophage roles in cardiac injury responses
While cTMsmay play an important role in cardiac homeostasis,
they are likely to be amongst the first cell types to react to
cardiac tissue damage. Following injury, a robust inflamma-
tory response involves secretion of various cytokines and
infiltration and mobilisation of multiple cell types. Inflamma-
tion recruits exogenous monocytes/macrophages that have
diverse functions (Fig. 4), distinct developmental origins and
bear a different phenotype to cTMs, and the ways in which
cTMs and invading monocytes/macrophages interact to
progress the wound healing response and influence each
other's phenotype are yet to be identified.
A major factor initiating the injury response cascade is
the necrosis-dependent release of intracellular contents andcellular debris, which is recognised by various cells presenting
PRRs, including cTMs (Pinto et al., 2012). These factors are
likely to override any intrinsic immune-dampening elements
and signal entry of neutrophils, the first exogenous myeloid
cells that peak in number within 24 h after injury. Neutrophils
phagocytose tissue debris and degranulate to release inflam-
matory mediators before submitting to phagocytosis by
macrophages. Monocytes next enter the lesion by homing
to soluble chemotactic cues such as MCP-1 and Cx3cl1, and
differentiate to macrophages (Nahrendorf et al., 2007;
Nahrendorf & Swirski, 2013). MCP-1 is a key monocyte/
macrophage chemoattractant and is produced by a range
of cardiac cells, including endothelial cells, macrophages
and fibroblasts, within hours following cardiac injury
(Dewald et al., 2005). Ablation of the Mcp-1 receptor
Ccr2 results in the severe impairment of the monocyte
influx into damaged tissue (Majmudar et al., 2013; Kaikita
et al., 2004).
After cardiac injury, two classes of macrophage are
sequentially predominant within damaged myocardium:
the classically activated ‘M1’, and alternatively activated
‘M2’ macrophages. The M1 and M2 paradigm, while an
710 A.R. Pinto et al.oversimplification, describes two broad and heterogeneous
macrophage classes at the extremes of a continuum of
maturation states (Mosser & Edwards, 2008). Extensive
research has established this model in wound healing and
inflammation in many tissues (Jenkins et al., 2011;
Nahrendorf et al., 2007; Arnold et al., 2007). Instrumental
for the study of M1 and M2 macrophages, particularly in the
mouse, has been the identification of cell surface markers
that have enabled their discrimination, such as Ly6C (where
M1 and M2 are Ly6Chigh and Ly6Clow, respectively), Mrc1 (also
known as CD206; where M1 and M2 macrophages are Mrc1−
and Mrc1+, respectively) and Cx3cr1 (where M1 and M2
macrophages are Cx3cr1low and Cx3cr1high, respectively)
(Nahrendorf et al., 2007; Arnold et al., 2007).
Within the first 5 days (the wound healing phase) and
peaking at approximately 3 days after cardiac injury, the M1
macrophage subtype predominates, characterised by their
fibrolytic, phagocytic and inflammatory properties, releasing
inflammatory mediators such as TNFα, IL-6, IL-1β, Ccl2, Ccl5
and nitric oxide (NO) (Nahrendorf et al., 2007; Murray &Wynn,
2011). M1 macrophages undertake extensive phagocytic
activity to clear necrotic and apoptotic debris including
remnant neutrophils, and release fibrolytic proteases such a
MMP-1, -2, -7, -9 and -12 which facilitates cells to penetrate
towards the injury lesion, paving the way for tissue
granulation.
Following the infiltration of M1 macrophages, approxi-
mately 7 days post-MI the injury-resolution phase begins
with M2 macrophages becoming predominant (Nahrendorf
et al., 2007). M2 macrophages are characterised as
anti-inflammatory, salutary, and fibrogenic (Murray & Wynn,
2011). Anti-inflammatory factors including IL-10, IGF-1 and
lipid mediators such as lipoxins, resolvins and protectins
(discussed above) drive resolution of the acute inflammatory
response.
M2macrophage-derived factors, such as FGF2, IGF-1, PDGF,
TGFβ1 and VEGF are angiogenic, limiting cell death due to lack
of blood supply (Nakao-Hayashi et al., 1992; Nahrendorf et al.,
2007; Grant et al., 1993b; Roberts et al., 1986). Angiogenesis is
also supported by M2 macrophage production of ECM modulat-
ing factors such as matrix metallopeptidases (MMPs) (Zijlstra et
al., 2004) and serine proteases (u-PA, t-PA) that liberate
ECM-bound growth factors and regulate both angiogenesis and
mobilisation of other cell types (Eming & Hubbell, 2011).
While M2 macrophages may be the principal drivers of
angiogenesis associated with injury resolution, M1 macro-
phages are highly fibrolytic, which may facilitate angiogenesis,
and secrete pro-angiogenic factors such as TNFα and IL-1β, and
nitric oxide (Sunderkotter et al., 1994; Cooke & Losordo,
2002). Therefore, both injury-associated macrophage subsets
may contribute to blood vessel growth, which is critical for the
minimization of cell death due to hypoxia.
The fibrogenic phenotype of M2 macrophages is a critical
element of cardiac healing by conferring cardiac tensile
strength and prevention of fatal cardiac rupture
(Nahrendorf & Swirski, 2013; Frangogiannis, 2012). M2
macrophages secrete a number of pro-fibrotic factors,
such as IGF-1, fibronectin 1 (FN1), Arg1, Retnla, TGFβ1,
FGF2 and others that promote fibrosis (Wynn & Barron,
2010; Bitterman et al., 1983; Goldstein et al., 1989). While
macrophage-derived FN1, collagen and other molecules
may directly contribute to ECM deposition, a majormechanism of macrophage-stimulated fibrosis is the acti-
vation of cardiac fibroblasts. M2 macrophage derived
factors such as IGF-1, Retnla, TGFβ1 and FGF2 can stimulate
fibroblast proliferation and also myofibroblast differentia-
tion (Bitterman et al., 1983; Goldstein et al., 1989).
While both phases of macrophage infiltration are critical
for resolving myocardial injury, it is increasingly becoming
evident that shifting the balance of macrophages to an
M2-like phenotype is salutary (Frangogiannis, 2012). For
example, inhibition of Ccr2-dependent entry of M1 macro-
phage forming monocytes after MI, by genetic ablation of
Ccr2 or RNAi, improves cardiac healing (Majmudar et al.,
2013; Kaikita et al., 2004). Indeed, cardiac-specific genetic
overexpression or direct delivery of M2-associated growth
factors such as IGF-1 or IL-10 is cardioprotective (Burchfield
et al., 2008; Santini et al., 2007).Macrophage-mediated stem cell regulation —
lessons from interactions between macrophages
and non-cardiac progenitors
In recent years, increased attention focused on macrophages
for stem cell activation in regenerating and neoplastic tissues
has underscored their role as guardians of the stem cell niche
that may be modulated to induce tissue regeneration
(Table 1). These studies offer valuable insights regarding the
potential role ofmacrophages, particularly cTMs, in regulating
the activities of intrinsic progenitor cells within the heart. Our
rapidly growing understanding of macrophages in these
contexts has relied on approaches that permit macrophage
depletion within defined temporal windows (see Chow et al.,
2011a) for comprehensive review). Clodronate-loaded lipo-
somes (Clo-Lip) specifically target phagocytic cells for de-
struction (Van Rooijen & Sanders, 1994), whereas myeloid/
macrophage-specific promoters drive genetic cassettes that
enable inducible cell death (for example diphtheria toxin
receptor (DTR) or Fas-ligands).
Using these approaches, macrophages have been identi-
fied as a critical component in tissue regeneration. For
example, Clo-Lip treatment following hepatic injury pre-
vents liver regeneration in mice (Boulter et al., 2012).
Similarly, Clo-Lip depletion of macrophages following mouse
skeletal muscle injury leads to derailment of the regenera-
tive programme and tissue scarring (Arnold et al., 2007),
comparable to the genetic blockade of M2 macrophage
generation (Ruffell et al., 2009). In salamanders, which
undergo efficient regeneration of whole body parts, tran-
sient depletion of macrophages using Clo-Lip within the first
four days following limb amputation alters the cytokine
profile and ECM composition preventing initiation of a
successful regeneration programme (Godwin et al., 2013).
Depletion of macrophages at later phases has no effect,
suggesting the early requirement for specific macrophage-
derived regenerative cues for regeneration. Blockade of
regeneration is not, however, permanent; reamputation of
the limb stump at a more proximal position, after replenish-
ment of macrophages, restores epimorphic regeneration of the
limb (Godwin et al., 2013). These observations confirm the
evolutionarily conserved role played by macrophages in the
initiation of tissue regeneration.
Table 1 In vivo regulation of stem cells by macrophages. Summary of in vivo studies implicating direct or indirect regulation of
stem cells by macrophages in tissue stress and homeostasis.
Tissue Stem cell MU targeting
approach
Effect of MU depletion MU paracrine
mediators
Reference
Liver Hepatic
progenitors
Clo-Lip Impairment of liver
regeneration, re-specification
of progenitor differentiation
Wnt3a Boulter et al. (2012)
Bone marrow Haematopoietic Clo-Lip,
CD169-DTR 1,
MaFIA 2
Stem cell mobilisation to
blood
Cxcl12 Chow et al. (2011b)
and Winkler et al.
(2010)
Heart Transplanted
mesenchymal
stem cells (MSCs)
Clo-Lip Impaired therapeutic effect
of MSCs
Unspecified Ben-Mordechai et al.
(2013)
Tumour Tumour stem cell Clo-Lip Induction of cancer stem cell
phenotype
Unspecified Yang et al. (2013)
Mammary
gland
Mammary stem
cells
Csf1op/op 3,
Clo-Lip
Impaired mammary
outgrowth of ectopic
mammary glands
Unspecified Gyorki et al. (2009)
Gut Colonic epithelial
progenitors (ColEPs)
Csf1op/op Loss of ColEP proliferation
after inflammatory stimulus
Unspecified Pull et al. (2005)
Lung Alveolar epithelial
type II cells (AE2)
LysM-DTR 4 Loss of AE2 cells; lung injury Unspecified Miyake et al. (2007)
1 Transgenic mouse line with diphtheria toxin receptor (DTR) driven by the CD169 promoter (Chow et al., 2011b).
2 Transgenic mouse line expressing Fas-based cell death gene driven by the c-fms promoter, enabling inducible macrophage depletion
(Burnett et al., 2004).
3 Mutant mouse line with deficiency in macrophage colony stimulating factor (CSF1) and macrophages.
4 Transgenic mouse line expressing DTR driven by the LysM promoter (Miyake et al., 2007).
711Macrophages in cardiac homeostasis, injury responses and progenitor cell mobilisationA key mechanism whereby macrophages may affect tissue
repair and regeneration is by instructing the stem cell niche by
paracrine mechanisms. In the mouse skeletal muscle injury
model, macrophage-derived paracrine factors promote satel-
lite cell survival, proliferation and differentiation in vitro and in
vivo (Cantini et al., 1994; Chazaud et al., 2003). In the mouse
hepatic injury model, phagocytic macrophages activate HPCs
via Wnt3a signalling, to induce HSP proliferation and differen-
tiation (Boulter et al., 2012). Depletion of macrophages sharing
the HPC niche results in re-specification of HPCs to generate
peri-portal biliary structures instead of hepatocytes (Boulter et
al., 2012).
Macrophages also occupy the haematopoietic stem cell
(HSC) niche (Chow et al., 2011b; Ludin et al., 2012; Winkler
et al., 2010). Macrophage depletion using either Clo-Lip,
macrophage-specific genetic or antibody-mediated depletion
strategies, results in egression of haematopoietic stem cells
(HSCs). Here, also, paracrine signalling is important with
Cxcl12 playing a prominent role (Chow et al., 2011b; Ludin et
al., 2012; Winkler et al., 2010; Christopher et al., 2011).
Depletion of bone marrow macrophages leads to a significant
decrease in Cxcl12 production (Chow et al., 2011b; Ludin et
al., 2012; Winkler et al., 2010; Christopher et al., 2011), a
critical factor for HSC homeostasis (Sugiyama et al., 2006).
Moreover, macrophage G-CSFR is important for regulation of
Cxcl12 and HSC mobilisation, with macrophage-restricted
G-CSFR expression sufficient for G-CSF mediated HSC
egression (Christopher et al., 2011). These observations
indicate that macrophages, in particular subepicardialcTMs, may act as gatekeepers regulating progenitor cell
mobilisation.
Macrophages likewise positively regulatemesenchymal stem
cells. In vitro experiments on cultured human MSCs demon-
strate that macrophage-derived growth factors enhance MSC
growth, viability, motility and secretion of paracrine factors
(Freytes et al., 2013; Anton et al., 2012). MSCmobilising factors
include IL-8, Mcp-1 and CCL5, which are chemotactic for MSCs
(Anton et al., 2012). However, macrophage-MSC interactions
are not uni-directional. MSCs transplanted to the injured
myocardium induce a shift in the balance of macrophages to
anM2-like phenotype (Ben-Mordechai et al., 2013). Similarly, in
a spinal cord injury model, MSC transplantation shifts macro-
phage phenotype to an M2-like phenotype, leading to improved
functional recovery (Nakajima et al., 2012). These findings are
consistent with in vitro evidence that supernatants from
cultured human MSCs polarise human monocyte-derived mac-
rophages towards M2-like cells (Kim & Hematti, 2009).
Finally, macrophages play a significant role in promoting
cancer stem cell proliferation and activation (De Palma &
Lewis, 2013). Tumour associated macrophages (TAMs), closely
resembling M2 macrophages (Pucci et al., 2009; Mantovani et
al., 2002), release a number of paracrine factors that regulate
cancer stem cells (CSCs) (De Palma & Lewis, 2013), including
those that induce tumour cells to acquire cancer stem cell-like
phenotypes (Yang et al., 2013; Jinushi et al., 2011). Depletion
ofmacrophages by either using Clo-Lip or synthetic inhibitors of
macrophage colony stimulating factor 1 receptor results in a
reduction in the number and activity of CSCs within tumours
712 A.R. Pinto et al.and increased sensitivity to chemotherapeutic agents (Yang et
al., 2013; Mitchem et al., 2013). Taken together, these
examples underscore the importance of macrophage-stem cell
cross talk for stem cell homeostasis and mobilisation. Consid-
ering the close interaction of cTMs with the epicardium (Pinto
et al., 2014), these observations indicate that cTMs may be
important for epicardial progenitor cell homeostasis and
potential maintenance of the progenitor cell phenotype.Challenges and future perspectives
While a significant body of work indicates that macrophages
are critical for tissue homeostasis, repair and regeneration,
much work is still required to delineate the precise
contribution of macrophages in these processes particularly
in the heart. Indeed, recent work has demonstrated that the
regeneration of the mouse neonatal heart and adult axolotl
heart is dependent on macrophages (Aurora et al., 2014;
Godwin, Pinto, Rosenthal, unpublished data). However, the
basic questions of whether macrophages are merely required
for clearance of tissue debris, an essential pre-requisite
process for tissue injury resolution, or whether they play a
greater role in directing cell fate and organogenesis remain
to be unequivocally demonstrated.
Addressing these primary questions or more focussed
questions such as macrophage-derived molecular mechanisms
is hampered by current technical limitations. Utilisation of
macrophage depletion and modulation strategies such as
Clo-Lip or genes driven by myeloid-specific promoters, main-
stays of macrophage biology, is not specific to injury lesions.
Therefore, whether the effects of perturbation derive from
local modulation of macrophages in the site of injury or
secondary effects in remote tissues (such as the spleen, liver
or bone marrow, for instance) is not clear. Deciphering the
precise molecular pathways for the activation of progenitor
cells in regenerative and non-regenerative tissues will
therefore necessitate the generation of new genetic tools.
In addition to identifying novel macrophage-mediated
regenerative signalling pathways, increasing macrophage
numbers in the injured heart may yield salutary results. As
cTMs are anti-inflammatory and modulation of inflamma-
tion by MSCs or other mechanisms improve cardiac repair,
cTM transplantation or expansion in situ may be therapeu-
tically beneficial following injury. Moreover, strategies to
reverse age-dependent changes in cTM gene expression
(Pinto et al., 2014), particularly in the epicardium, may
improve inflammatory signalling profiles in response to
injury or stress.
The last ten years has seen a dramatic expansion in our
understanding of this most versatile cell type. However, while
important work has been done regarding the role of exogenous
macrophages in cardiac injury, our understanding of the role
of cTMs for cardiac development and homeostasis is currently
superficial and limited to interpretation of gene expression
data. It is unknown what role cTMs may play in cardiac
development at the structural and functional level. Moreover,
the contribution of macrophages to cardiac inflammatory
responses is unclear and the dynamic interplay between cTMs
and cardiac progenitors is unresolved. New approaches are
required to modulate macrophage numbers and gene expres-
sion in the heart with greater specificity. Nevertheless,evidence gathered to date suggests that the manipulation of
macrophages in the heart is worthy of further investigation,
and may be pivotal for reducing morbidity and mortality
following cardiac injury.Acknowledgments
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